BeyondSpring (BYSI) Capital Expenditures (2016 - 2026)
BeyondSpring (BYSI) posted Capital Expenditures of $52000.0 for Q1 2026, up 4.0% sequentially from $50000.0 in Q1 2025, and up 4.0% YoY from $50000.0 in Q1 2025.
BeyondSpring (BYSI) Capital Expenditures (2016 - 2026) Analysis & Trends
BeyondSpring has reported Capital Expenditures for 9 years, with the latest figure at $52000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 4.0% year-over-year to $52000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52000.0 (down 74.0% YoY) and the FY2025 annual result came in at $50000.0, down 77.68% from the prior year.
- Capital Expenditures improved to $52000.0 in Q1 2026 per BYSI's latest filing, from $50000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $120000.0 in Q3 2024 and troughed at $3000.0 in Q2 2024.
- A 3-year average of $54333.3 and a median of $51000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures sank 32.43% in 2025, then climbed 4.0% in 2026.
- Over 3 years, Capital Expenditures stood at $27000.0 in 2024, then soared by 85.19% to $50000.0 in 2025, then advanced by 4.0% to $52000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $52000.0, $50000.0, and $27000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,000.00 |
| Jun 30, 2026 | 11,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 74,000.00 |
| Mar 31, 2024 | 74,000.00 |
| Dec 31, 2021 | 2.76 Mn |
| Dec 31, 2021 | 2.76 Mn |
| Sep 30, 2021 | -28,000.00 |
| Sep 30, 2021 | -28,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |